Protein

Civetta Therapeutics Unveils a Propeller Protein Plan, $53M in Funding

6 days ago   |   By Xconomy

New biotech company Civetta Therapeutics has closed a $53 million Series A financing round to develop drugs that target “propeller proteins” as a way of treating cancers and other diseases. Propeller proteins are found throughout nature, and the circularly arranged “blades” of these proteins commonly serve as active sites to which molecules can bind. Bruce Goldsmith, a venture partner at Deerfield Management and Civetta's interim CEO, says propeller domains, the structural scaffolds of these proteins, have not been “fully exploited” for therapeutic drug discovery. “Propeller domains have...
Read more ...

 


Search by Tags

   Protein      Nature      Drugs      Drug      Therapeutics      Biotech      BioTech      Cancer      Discovery      Boston      Boston blog main      National      National blog main      Dana-Farber Cancer Institute      Life Sciences      Oncology      The Broad Institute of MIT and Harvard  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Perceptive Unveils New $200M Fund to Invest in Early-Stage Biotechs

Perceptive Unveils New $200M Fund to Invest in Early-Stage Biotechs

Perceptive Advisors, an investment firm with a long track record of life science investing across all points of development, is now stepping up to pump money into companies at... Read more ...

Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule

Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule

Merck is acquiring cancer drug developer ArQule for $2.7 billion , a cash deal that brings it a promising early-stage compound that could challenge a blockbuster leukemia drug... Read more ...

KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test

KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test

A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial. KalVista developed its drug, KVD001, to treat... Read more ...

Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules

Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules

Zentalis Pharmaceuticals is banking on small molecules for cancer-leaving the “cool technologies” aside for a “tried and true” approach, says the CEO, who wants to let the... Read more ...

Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer

Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer

The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other... Read more ...

Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego's Synthorx

Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego's Synthorx

Synthorx is working to design new cytokine therapies for cancer using an “extended” genetic alphabet that could help avoid the shortcomings associated with earlier versions... Read more ...

Artificial Pancreas Keeps Patients Healthier: A Perspective

Artificial Pancreas Keeps Patients Healthier: A Perspective

The late Mayo endocrinologists Russell Wilder, M.D., and Randall Sprague, M.D., would be smiling today at the news for patients with diabetes. Much of their lives and careers... Read more ...

Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals

Aurinia Plans FDA Filing After Lupus Nephritis Drug Hits Phase 3 Goals

Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary and secondary endpoints in a Phase 3... Read more ...

AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets

AstraZeneca Taps Gatehouse Bio to Identify Potential Drug Targets

After joining AstraZeneca's Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and... Read more ...

Clinical Trial Assistant - Vanguard Clinical Inc - Solana Beach, CA

Demonstrated strengths in planning, organization, time management, problem solving, and attention to detail. Create meeting agenda/minute templates and provides... $70,000... Read more ...